AbbVie Says It Can Be First With New Hepatitis C Drugs

AbbVie Inc. said it can win the race against Gilead Sciences Inc. to bring to market a new generation of all-oral hepatitis C drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.